People: Strategic Diagnostics Inc. (SDIX.O)

SDIX.O on Consolidated Issue listed on NASDAQ Global Market

1.44USD
9 Feb 2010
Price Change (% chg)

$0.02 (+1.41%)
Prev Close
$1.44
Open
--
Day's High
$1.47
Day's Low
$1.40
Volume
5,495
Avg. Vol
8,028
52-wk High
$2.25
52-wk Low
$0.85

view people for:

Summary

Name Age Since Current Position
DiNuzzo, Francis 53 2008 President, Chief Executive Officer
Bratton, Kevin 58 2009 Chief Financial Officer, Vice President - Finance
Stave, James 54 1993 Vice President - Research & Development, Chief Scientific Officer
Lindpaintner, Klaus 2010 Vice President - Research & Development, Chief Scientific Officer
Barbara, Deborah 2008 Vice President - Business Development
Fronczkowski, Stanley 57 2009 Corporate Secretary
Waechter, Stephen 59 2002 Director
Spiro, Clifford 55 2006 Director
Davis, C. Geoffrey 58 2007 Director
Becker, Steven 42 2008 Director
Van den Broek, Richard 43 2008 Director
» Insider Trading

Biographies

Name Description
DiNuzzo, Francis Mr. Francis M. DiNuzzo is President and Chief Executive Officer of Strategic Diagnostics Inc. He was Interim President and Interim Chief Executive Officer of Strategic Diagnostics Inc. till October 2008. He joined Strategic Diagnostics Inc. in February 2008 as Executive Vice President – Marketing and Chief Commercial Officer. Prior to joining SDI, Mr. DiNuzzo spent 26 years at Agilent Technologies / Hewlett Packard. He began his career in research and devselopment in 1981 and advanced through a series of functional management over the next 18 years. In 1999, Mr. DiNuzzo became General Manager of Agilent’s Chemical Solutions Business Unit where he had global responsibility for analytical equipment, consumables and service products serving the chemical, environmental, food and forensics markets. In 2001, Mr. DiNuzzo became General Manager of the Consumable and Services Business Unit, with global responsibility for all consumables and services across all Life Science and Chemical Analysis markets. In 2004, Mr. DiNuzzo became Vice President and General Manager of the Integrated Biology Solutions unit, a role where he formed a biotechnology business focused on Genomics, Proteomics and BioInformatics. Mr. DiNuzzo holds B.S and M.S. degrees in Engineering with a minor in Business Administration from the University of New Hampshire. Mr. DiNuzzo serves on the Board of Directors of Delaware Bioscience Association.
Bratton, Kevin Mr. Kevin J. Bratton is Chief Financial Officer, Vice President - Finance of Strategic Diagnostics Inc. Mr. Bratton has over 35 years of experience in all phases of multi-national financial operations across the healthcare, biotechnology and technology industries, including developing strategic plans and annual budgets as well as financing negotiations and merger & acquisition transactions. Most recently at EUSA Pharma (USA), Mr. Bratton's responsibilities included business development and sales in Latin America and Canada. At Cytogen, he led the financial review of strategic alternatives resulting in an acquisition by EUSA Pharma, Inc. Prior to joining Cytogen, Mr. Bratton was Chief Financial Officer at Metrologic Instruments, Inc., a global technology company, where he directed the company's finance operations during a period of significant growth in sales, net income, cash flow from operations, and working capital. Previously, Mr. Bratton worked at The JPM Company, where he served as chief financial officer and as director of external reporting. Prior to joining JPM, Mr. Bratton worked for more than 20 years in the healthcare sector. He was vice president of finance and treasurer for the biotechnology company IGI, Inc., and corporate controller for the specialty medical company Delmed, Inc. Mr. Bratton began his career with the public accounting firm Touche Ross & Co. (now Deloitte & Touche LLP). He has a bachelor of science in business and accounting from Northeastern University.
Stave, James Mr. James W. Stave is Vice President - Research & Development, Chief Scientific Officer of Strategic Diagnostics Inc. He joined the Company in March 1991 as a research group leader. Subsequently, Dr. Stave was promoted to Director of Research and Development. In October 1993, Dr. Stave was promoted to Vice President—Research and Development and Chief Technical Officer. Dr. Stave was elected Chief Science Officer in 2006. Prior to joining SDI, Dr. Stave worked for DuPont, Molecular Genetics, Inc. and the U.S. Department of Agriculture. Dr. Stave received his Ph.D. in Microbiology from the University of Maryland and his B.S. in Biology from Michigan Technological University.
Lindpaintner, Klaus Dr. Klaus Lindpaintner has been appointed as Vice President of Research & Development and Chief Scientific Officer of Strategic Diagnostics Inc. effective February 1, 2010. Prior to joining SDI, Dr. Lindpaintner was with F. Hoffmann-La Roche Ltd. and most recently served as Director of the "Roche Molecular Medicine Laboratories" at the company's headquarters in Basel, Switzerland, and as Roche's Global Head, Molecular Medicines Policy and External Affairs, coordinating the company's efforts and activities in implementing biomarker research based on genetics, genomics, proteomics, and associated disciplines from early discovery to late-stage clinical trials. He has co-authored more than 200 scientific papers, and has held honorary and adjunct professorships at the University of London Guy's and St. Thomas, Jiao Tong University in Shanghai, Stanford University and the University of Vienna. Dr. Lindpaintner is a member of a number of Editorial Boards, including The Pharmacogenomics Journal, J Comm Biotechnology, and Pharmacogenomics. He is a co-inventor on several patents. Dr. Lindpaintner graduated from the Innsbruck University Medical School with a degree in Medicine and from Harvard University with a degree in Public Health. He pursued postgraduate training and specialization in Internal Medicine, Cardiology, and Genetics in the United States and Germany and holds board certifications in these specialties. Prior to joining industry, he practiced clinical cardiology and pursued academic research in the areas of cardiovascular disease, molecular genetics, and genetic epidemiology as an Associate Professor of Medicine at Harvard Medical School. He is a Fellow of the American College of Physicians, the American Heart Association, and the American College for Medical Genetics.
Barbara, Deborah Ms. Deborah Day Barbara has been appointed as Vice President - Business Development of Strategic Diagnostics Inc., effective October 13, 2008. Ms. Barbara was most recently Vice President of Business Development and Licensing for Ore Pharmaceuticals in Gaithersburg, Maryland. Ms. Barbara has over 20 years of experience in the areas of business development, licensing, intellectual property management, strategic planning and technology development. While working at Ore Pharmaceuticals, Ms. Barbara led drug evaluation partnership negotiations with several prominent pharmaceutical companies, resulting in valuable business relationships and a pipeline of clinical stage drug candidates. Immediately prior to joining Ore Pharmaceuticals, Ms. Barbara was Senior Director of Business and Technology Development for Johns Hopkins University, and was responsible for developing numerous licensing and research agreements. She also spent 11 years at Amersham Life Sciences in a variety of sales leadership positions.
Fronczkowski, Stanley Mr. Stanley Fronczkowski has been appointed as Corporate Secretary of Strategic Diagnostics Inc effective June 1, 2009. He has served as Vice President - Finance, Chief Financial Officer and Corporate Secretary of Strategic Diagnostics Inc since January 2007. Prior to joining SDI, Mr. Fronczkowski spent 29 years with Keystone Foods. He began his career with Keystone in 1978, rising to the position Vice President, International Finance in 1988, and over the next 10 years, supported Keystone’s growth across multiple companies on four continents. In 1998, Mr. Fronczkowski became COO for Keystone Europe, Middle East and Africa with full responsibility for the operating results of this business group. Following Keystone’s reorganization to Strategic Business Units in Europe and North America, Mr. Fronczkowski assumed his most recent assignment as Keystone’s Vice President for Finance, Asia-Pacific. Mr. Fronczkowski is a graduate of the State University of New York at Cortland with a B.S in Political Science, the University of Delaware with a B.S. in Accounting, and Widener University with a M.S. in Finance and Taxation.
Waechter, Stephen Mr. Stephen L. Waechter is Director of Strategic Diognostics Inc since 2002. Mr. Waechter served as Executive Vice President, Chief Financial Officer and Treasurer of CACI International Inc, a leading provider of information technology services and solutions, from April 1999 through January 2007. From 1997 to 1999, he served as Executive Vice President, Chief Financial Officer and Treasurer of GTSI, Corp., a provider of integrated information technology solutions. Mr. Waechter serves on the Advisory Board of the Junior League of Northern Virginia. He holds a B.A. in History from Christian Brothers College and received an M.B.A. from Xavier University.
Spiro, Clifford Mr. Clifford L. Spiro has served as a Director of Strategic Diagnostics Inc since 2006. Dr. Spiro currently serves as the Vice President of Research and Development for Cabot Microelectronics Corporation, the Supplier of chemical-mechanical-planarization technologies that are critical to the successful production of semiconductors and data storage devices. In 2001, Dr. Spiro was named Vice President of R&D for the Nalco subsidiary of Suez Corporation, a leader in water, paper, and energy chemicals. From 1980 through 2001, he held a series of progressively responsible research and management positions at General Electric Company. Dr. Spiro holds 19 US Patents and has published 80 scientific articles and coauthored 55 conference presentations. He has served as a Director on the Board of the Mississippi Polymer Technologies Corporation and Maxdem Corporation. Dr. Spiro received a B.S. degree with honors in chemistry from Stanford University and a Ph.D. degree in chemistry from Caltech.
Davis, C. Geoffrey Mr. C. Geoffrey Davis, Ph.D. is Director of Strategic Diognostics In in September 2007. Currently, Dr. Davis is the CEO and Chairman of Angelica Therapeutics, Inc., a privately held biotechnology company. In 1996, Dr. Davis founded Abgenix, Inc. in Fremont, California, where he served as the Chief Scientific Officer and led the development of the XenoMouse® technology and was involved in the research and development of Vectibix®, a fully human monoclonal antibody approved for the treatment of colorectal cancer. Dr. Davis also guided the discovery of 11 other antibodies currently in clinical trials. Abgenix was acquired by Amgen in early 2006. Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc. Dr. Davis received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at Southwestern University. He is the author of 37 publications and is an inventor on 11 issued patents. Mr. Davis serves as a Director of Harbour Antibodies, AB and is a member of the National Board of Directors of the Leukemia and Lymphoma Society.
Becker, Steven Mr. Steven R. Becker is Director of Strategic Diognostics Inc in March 2008. Mr. Becker has served as the managing partner and founder of Greenway Capital, a Dallas-based small cap investment fund, since September 2004. Greenway focuses primarily on investing in small public companies with a concentration in healthcare and technology businesses. Prior to founding Greenway, Mr. Becker was a partner at the Special Situations Fund, a New York City based asset manager. Mr. Becker joined Special Situations Fund in April 1997 and ran the Special Situations Private Equity Fund since its inception. Mr. Becker was also a partner in the Special Situations Fund III, the firm’s flagship investment vehicle, which focused on investing in micro cap value stocks. Prior to joining Special Situations, Mr. Becker was part of the distressed debt and leveraged equities research team at Bankers Trust Securities. He began his career at Manley Fuller Asset Management in New York as a small cap analyst. Mr. Becker received a B.A. from Middlebury College and a J.D. from the University of Florida.
Van den Broek, Richard Mr. Richard Van den Broek is Director of Strategic Diagnostics Inc Since March 2008. Since 2004, Mr. van den Broek has been Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. Mr. van den Broek is a graduate of Harvard University and is a Chartered Financial Analyst.

Insider Trading

Name Shares Traded Price
LINDPAINTNER KLAUS 25,000 $0.00
BECKER STEVEN R 17,900 $1.65
BECKER STEVEN R 5,800 $1.64
BECKER STEVEN R 12,400 $1.60
BRATTON KEVIN J 25,000 $0.00
WAECHTER STEPHEN L 2,500 $0.00
SPIRO CLIFFORD L 2,500 $0.00
DAVIS CLAUDE GEOFFREY 2,500 $0.00
VAN DEN BROEK RICHARD 2,500 $0.00
BECKER STEVEN R 2,500 $0.00
LOTMAN HERBERT 19,190 $1.18
SPIRO CLIFFORD L 10,000 $1.00
DINUZZO FRANCIS M 7,700 $1.05
DINUZZO FRANCIS M 2,300 $1.02
DAVIS CLAUDE GEOFFREY 15,730 $0.00
SPIRO CLIFFORD L 20,224 $0.00
COLLINS MORTON 20,224 $0.00
WRENN GROVER C 42,696 $0.00
BECKER STEVEN R 15,730 $0.00
WAECHTER STEPHEN L 26,966 $0.00
LOTMAN HERBERT 15,730 $0.00
VAN DEN BROEK RICHARD 15,730 $0.00
COLLINS MORTON 20,000 $0.81
BECKER STEVEN R 641,554 $1.00
SPIRO CLIFFORD L 100 $2.40
» Full list on Insider Trading
view people for: